Latest News- Chronic Kidney Disease (CKD) Drugs Market: Erythropoietin stimulating agents is expected to lead the Drug Class segment during 2025-2029

The Chronic Kidney Disease (CKD) Drugs Market is being driven by Rising prevalence of CKD globally

The Chronic Kidney Disease (CKD) Drugs Market is expected to grow at a CAGR of 4.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 4075.9 million. Pharmaceutical firms are making noteworthy advancements in the research and development of innovative drugs for the treatment of Chronic Kidney Disease (CKD). Regulatory agencies globally are emphasizing the significance of addressing the unmet medical requirements in CKD treatment, leading to an escalating number of drug approvals. For instance, in January 2023, Boehringer Ingelheim and Eli Lilly and Company submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Jardiance (empagliflozin) tablets. These tablets are currently under investigation as a potential therapy to decrease the risk of kidney disease progression and death due to cardiovascular disease in adults with CKD. This approval represents a significant milestone in the treatment landscape for CKD patients. 

Get more information on Chronic Kidney Disease (CKD) Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Drug Class
  • Erythropoietin stimulating agents
  • Calcium channel blockers
  • Phosphate binders
  • ACE inhibitors
  • Others
• Route Of Administration
  • Oral
  • Subcutaneous
  • Intravenous
• Distribution Channel
  • Offline
  • Online
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Rising prevalence of CKD globally
• Increase in healthcare expenditure globally
• Growing awareness about need for early detection and diagnosis of CKD

However, the market also witnesses some limitations, which are as follows:

• High costs associated with CKD treatment
• Stringent regulatory guidelines for CKD drugs
• Growing competition from generic CKD drugs

Benefits of Buying Global Chronic Kidney Disease (CKD) Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Chronic Kidney Disease (CKD) Drugs Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Chronic Kidney Disease (CKD) market encompasses various treatments including nephrotoxic drugs, contrast agents, and lifestyle modifications such as dietary restrictions (sodium, potassium, phosphorus), fluid restriction, and Calcium and Vitamin D supplements. Erythropoiesis-stimulating agents, Iron supplements, kidney transplant (for kidney donors and recipients), immunosuppressive therapy, and treatments for specific conditions like Diabetic Nephropathy, Hypertensive Nephropathy, Interstitial Nephritis, and Renal Tubular Acidosis are also part of this market. Nephrotoxic drugs and contrast agents can cause kidney damage, while dietary modifications and supplements help manage symptoms and prevent complications.

Market Research Overview

The Chronic Kidney Disease (CKD) drugs market is a significant segment of the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of various types of drugs, including generics, non-generics, and veterinary medicines. According to Technavio's market analysis, the global pharmaceuticals market's growth is primarily driven by demographic trends, such as the increasing population aging. By 2050, approximately one-quarter of the US population and by 2030 in Europe are projected to be over 60 years old. This demographic shift will lead to a higher prevalence of CKD, thereby boosting the demand for associated treatments. Specifically, the CKD drugs market will witness significant growth due to the increasing usage of Creatinine Clearance tests, Peritoneal Dialysis, Kidney Transplantation, Renin Inhibitors, and SGLT2 Inhibitors.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/